This Plain Language Summary of publication article (PLSP) from Immunotherapy looked at how benralizumab impacted asthma control, reduced the need for oral corticosteroids, improved lung function, and decreased asthma attacks. Patients were treated for an average of 10.3 months, with some treated for up to 96 weeks.

Visit the site using this link to read the article.

This PLSP is based on articles called:

‘ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study’ published in Respiratory Research

‘Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study’ published in Respiratory Research

‘Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis’ published in Frontiers in Allergy

‘Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis’ published in Frontiers in Medicine.

Visit BMC using the link to read original article

Visit BMC using the link to read original article

Visit Frontiers using the link to read original article

Visit Frontiers using the link to read original article.